We are live on ! Find out more

Supernus Pharmaceuticals

SUPN

Market cap $2.37B

40.70 USD

-1.37

3.26%

At close Updated Oct 23, 4:00 PM EDT

Pre-market

After hours

40.70

0.00

0%

1 day

-3.26%

5 days

7.76%

1 month

-6.2%

3 months

-13.75%

6 months

-19.23%

Year to date

-17.73%

1 year

-21.76%

5 years

35.08%

10 years

97.09%

About: Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

Employees: 778

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 40%

Neutral 50%

Negative 10%

Zacks Investment Research

Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline

Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline

Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)

Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGO Additionally, the Company submitted an sNDA to the FDA for a second supplier for ONAPGO, with potential approval by mid-year 2027 ROCKVILLE, Md., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that the U.S. Food and Drug Administration (FDA) has recognized seven years of orphan-drug exclusive approval for ONAPGO (apomorphine HCl) for the treatment of motor fluctuations in adults with advanced Parkinson's disease.

Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)

Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026

ROCKVILLE, Md., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will report third quarter 2026 financial and business results after the market closes on Thursday, October 29, 2026.

Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026

Supernus Pharmaceuticals: The Merger Is Priced Like A Retreat, But Reads Like A Reverse Takeover

Supernus Pharmaceuticals merges with Indivior, gaining operational control and exposure to a larger, cash-generating CNS and addiction platform. SUPN's growth products now comprise 80% of revenue, with Qelbree and ZURZUVAE driving robust prescription and sales growth. Combined entity targets $2.2B revenue, $888M adjusted EBITDA, $125M synergies, and trades at ~7x synergized EBITDA—suggesting a mispriced, underappreciated value.

Supernus Pharmaceuticals: The Merger Is Priced Like A Retreat, But Reads Like A Reverse Takeover

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN) to Indivior Pharmaceuticals, Inc. (Nasdaq: INDV). Under the terms of the proposed transaction, shareholders of Supernus will receive 1.5401 common shares of Indivior for each share of Supernus that they own. KSF is seeking to determine whether thi.

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

Supernus Pharmaceuticals to Participate in September Investor Conferences

ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following September investor conferences:

Supernus Pharmaceuticals to Participate in September Investor Conferences

Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD

ROCKVILLE, Md., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Professional snowboarder, Chloe Kim, is partnering with Supernus Pharmaceuticals as a compensated ambassador to discuss her journey with attention-deficit/hyperactivity disorder (ADHD) and her treatment plan with Qelbree (viloxazine extended-release capsules), a once-daily, non-stimulant medication for patients 6 years and older. Designed for flexible once-a-day routine integration, Qelbree offers 24-hour medication exposure, no evidence of abuse potential, and versatile administration options, including the ability to be sprinkled and taken at any time of day (either morning or night). Through this partnership, Chloe Kim will open up about her own diagnosis to challenge misconceptions about ADHD. By sharing her lived experience, she will encourage others to advocate for their health and initiate collaborative conversations with their doctors about a potential treatment plan.

Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD

SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) to Indivior Pharmaceuticals, Inc. for 1.5401 common shares of Indivior for each share of Supernus.Halper Sadeh encourages Supernus shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected] investigation con.

SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

Zacks Investment Research

Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock?

Investors need to pay close attention to SUPN stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock?

Zacks Investment Research

Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026

INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on Sublocade, but closing remains uncertain.

Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026

See News Rankings

Price charts implemented using Lightweight Charts™